1. Boise LH, Minn AJ, Noel P, June CH, Accavitti MA, Lindsten T, Thompson CB (1995) CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3:87
2. Del Bello B, Valentini MA, Zunino F, Comporti M, Maellaro E (2001) Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Oncogene 20:4591
3. Demir G, Ozguroglu M, Sayhan N, Molinas-Mandel N, Demirelli F, Buyukunal E, Tuzuner N, Serdengecti S, Berkarda B (1999) Immunomodulating therapy with rIL-2 and interferon alpha indices in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study). Anticancer Res 19 (4C):3517
4. Demke W, Rie C, Grothey A, Schmoll H-J (2001) Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clinical Oncol 127:411
5. Esche C, Shurin GV, Kirkwood JM, Wang G-Q, Rabinowich H, Pirtskhalaishvili, Shurin MR (2001) Tumour necrosis factor-α-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res 7:974s